GSDME Knockout BxPC-3 Cell Line

The GSDME Knockout BxPC-3 Cell Line is a CRISPR/Cas9-edited knockout cell line in which the GSDME gene has been disrupted in the BxPC-3 human pancreatic adenocarcinoma background. This model provides a loss-of-function system for investigating gasdermin E-mediated pyroptosis and its role in converting apoptosis to inflammatory cell death. By eliminating GSDME expression, researchers can study the functional consequences on cell death signaling and innate immune activation, enabling robust comparative analyses with parental BxPC-3 cells.

BxPC-3 is a pancreatic ductal adenocarcinoma cell line derived from a primary tumor of a 61-year-old female. It is characterized by wild-type KRAS and a TP53 mutation, which distinguishes it from KRAS-mutant pancreatic cancer models and makes it valuable for studying KRAS-independent pathways and p53-related tumor suppressor networks. This adherent epithelial line is extensively used in cancer cell biology, drug discovery, and cell death research.

GSDME (gasdermin E) is a pore-forming executor of pyroptosis that is cleaved by caspase-3 upon apoptotic signaling. Initiated by the mitochondrial pathway or death receptor engagement, caspase-3 activation leads to release of an N-terminal GSDME fragment that oligomerizes in the plasma membrane, creating pores that cause cell swelling, lysis, and secretion of pro-inflammatory mediators including IL-1??, IL-18, and HMGB1. This process transforms a non-inflammatory apoptosis into an inflammatory pyroptotic death. GSDME activity is regulated by upstream factors such as caspase-3, granzyme B, TNF, FasL, and chemotherapeutic drugs, and it interacts with caspase-3, GSDMD, BAX, BAK, and Apaf-1 within the broader mitochondrial apoptosis network comprising cytochrome c, caspase-9, and BCL-2 family members.

In the BxPC-3 setting, this knockout model is particularly relevant because the cell line’s unique genetic profile??wild-type KRAS and TP53 mutation??offers a distinct landscape to study p53-independent pyroptotic responses elicited by chemotherapeutics. Ablation of GSDME allows precise dissection of apoptotic versus pyroptotic cell death modes and their impact on drug sensitivity, tumor microenvironment cross-talk, and inflammatory signaling, thereby addressing key questions in pancreatic cancer biology.

Applications include investigation of pyroptosis in pancreatic cancer, chemotherapy-induced cytotoxicity, and inflammatory cell death mechanisms. Key assays such as western blot for GSDME cleavage, LDH release for lytic death, caspase-3 activity measurements, Annexin V/PI flow cytometry, and IL-1?? ELISA facilitate thorough characterization. Drug sensitivity screening and live-cell imaging further enable real-time analysis of treatment responses, while transcriptomic profiling by RNA-seq can uncover pyroptosis-associated gene expression changes. For further technical details and validation data, please contact Ascent Research.